Day One Biopharmaceuticals, Inc. (DAWN) Revenue History
Annual and quarterly revenue from 2019 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
DAWN Revenue Growth
Revenue Breakdown (FY 2025)
DAWN's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
DAWN Revenue Analysis (2019–2025)
As of May 8, 2026, Day One Biopharmaceuticals, Inc. (DAWN) generated trailing twelve-month (TTM) revenue of $158.2 million, reflecting explosive growth of +83.9% year-over-year. The most recent quarter (Q4 2025) recorded $53.7 million in revenue, up 35.0% sequentially.
Looking at the longer-term picture, DAWN's historical revenue data shows various trends over time. The company achieved its highest annual revenue of $158.2 million in 2025, representing a new all-time high.
Revenue diversification analysis shows DAWN's business is primarily driven by Product (98%), and License (2%). With over half of revenue concentrated in Product, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including KURA (+25.2% YoY), TGTX (+81.3% YoY), and RCUS (+67.4% YoY), DAWN has outperformed the peer group in terms of revenue growth. Compare DAWN vs KURA →
DAWN Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| DAWNCurrent | $158M | +83.9% | - | -80.8% | |
 KURA | $67M | +25.2% | - | -449.9% | |
 TGTX | $616M | +81.3% | +426.7% | 20.0% | |
 RCUS | $247M | +67.4% | +25.9% | -156.3% | |
 FOLD | $634M | +20.0% | +19.4% | 5.4% |
DAWN Historical Revenue Data (2019–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $158.2M | +20.6% | $141.0M | 89.1% | $-127,750,000 | -80.8% |
| 2024 | $131.2M | - | $125.9M | 96.0% | $-217,270,000 | -165.7% |
| 2023 | $0 | - | $-383,000 | - | $-206,064,000 | - |
| 2022 | $0 | - | $-531,000 | - | $-146,909,000 | - |
| 2021 | $0 | - | $-199,000 | - | $-72,743,000 | - |
| 2020 | $0 | - | $-155,000 | - | $-13,782,000 | - |
| 2019 | $0 | - | $0 | - | $-14,905,000 | - |
See DAWN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs DAWN Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare DAWN vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonDAWN — Frequently Asked Questions
Quick answers to the most common questions about buying DAWN stock.
Is DAWN's revenue growth accelerating or slowing?
DAWN revenue is accelerating at +83.9% year-over-year, exceeding the 5-year CAGR of N/A. TTM revenue reached $158M. Growth momentum has increased versus prior periods.
What is DAWN's long-term revenue growth rate?
Day One Biopharmaceuticals, Inc.'s 5-year revenue CAGR of N/A reflects the sustained expansion pattern. Current YoY growth of +83.9% is above this long-term average.
How is DAWN's revenue distributed by segment?
DAWN reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2019-2025 are available for download. Segment mix reveals concentration and diversification trends.